



Bringing Advanced Energy to Endoscopy

Anything is Possible with the Right Approach

IMPORTANT NOTICE

This presentation comprises the written materials/slides (“presentation”) concerning Creo Medical Group PLC (the “Company”) and technologies and/or products developed or under development by the Company. By reviewing this presentation you agree to be bound by the following terms and conditions:

- No reliance may be placed for any purposes whatsoever on the information in this presentation or on its completeness. The presentation is intended to provide a general overview of the Company including its business, technology and products, and does not purport to deal with all aspects and details regarding the Company. Accordingly, neither the Company nor any of its respective directors, officers, employees or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance may be placed on, the fairness, accuracy or completeness of the information contained in the presentation or of the views given or implied.
- Neither the Company nor any of its respective directors, officers, employees or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this presentation or any information or contents herein or otherwise arising in connection therewith.
- Certain statements in this presentation are or may be forward looking statements. These forward looking statements are neither historical facts or guarantees of future performance. Such statements are based on current expectations and belief and, by their nature, are subject to a number of known and unknown risks and uncertainties which may cause the actual results, prospects and developments of the Company to differ materially from those expressed or implied by these forward looking statements.
- The information contained in this presentation is for background purposes only. The subject matter of the presentation may be subject to change and the Company does not take any responsibility for updating or amending the contents to reflect such changes. The material contained in this presentation reflects current legislation and the business and financial affairs of the Company which are subject to change without notice and audit and is subject to the provisions contained within legislation.
- The slides of this presentation summarise the information presented. Without prejudice to the generality of these conditions, these slides, including any views given or implied, or any statement made, in relation to such information should not be relied upon, nor should it be treated as accurate or complete. This presentation and all such information contained herein should be read subject to the Company's latest annual or interim results.
- The information contained in this presentation has been obtained from Company sources and from sources which the Company believes to be reliable but it has not independently verified such information and does not guarantee that it is accurate or complete.
- No statement in this presentation is intended to be a profit forecast and no statement in this presentation should be interpreted to mean that earnings per Company share for current or future financial years would necessarily match or exceed the historical published earnings per Company share.

The Evolution of Advanced Energy



1. Coherent Market Insights, Laparoscopic Devices Market Analysis – Jan 2020. 2. Boston Scientific investor presentation, 2015. 3. Conmed investor presentation, August 2016 4. Intuitive 2021 Earnings Estimate presentation and Creo market analysis. 5 JAMA Network Open. 2020;3(1):e1918911. doi:10.1001/jamanetworkopen.2019.18911



1800-1970

1970-1990

Golden Era

Open surgery

Open surgery remains as standard of care, but availability of fibre optic and CCD endoscopes leads to development of early endoscopic devices




1990-2010


Surgical milestone

Keyhole/Laparoscopic surgery overtakes open surgery, accounting for 75% of all procedures

\$10.15bn
Laparoscopic Instrument Market¹
Centred around Johnson & Johnson, Medtronic and Olympus/Gyrus



2010-2025



Paradigm Shift

Advances in single-port laparoscopy, robotic surgery, natural orifice transluminal endoscopic surgery & **flexible endoluminal endoscopy** herald a new era of healthcare

\$3-4bn GI Endoscopic Instrument Addressable Market^{2,3}
with minimal competition

Break even 2023/2024

Robotic Advanced Energy

Robotic surgery accounts for circa 5% of all procedures.⁵
Over 2m pa Robotic Procedures, **growing fast.**⁴

Surgical Robotics market growing at a 14-20%+ CAGR.⁵

Hospitals adopting RAS experienced general surgery procedure utilisation increase from <2% RAS to >15% RAS in 6 years⁵

Dominant Handheld Technology inappropriate for Robotic Applications

Creo Medical Overview

**\$3-4bn GI Endoscopic
Instrument Addressable
Market^{1,2}**
with minimal
competition

- Creo Medical develops and commercialises **a suite of electrosurgical medical devices**, each enabled by its CROMA platform, **powered by Kamaptive™ Technology**
- Kamaptive Technology provides clinicians with **increased flexibility, precision, and controlled** surgical solutions
 - **Endoscopic** devices mean procedures are:
 - Minimally-invasive, easy-to-use and cost effective
 - Dramatically reduce complications and times
 - Deliver excellent patient outcomes
- **>1000 procedures to-date** with >100 customers trained and >350 in pipeline
 - New user being added each week
 - Moving from multiple cases monthly, through multiple cases weekly to now multiple cases daily on a global basis
 - Focus remains to increase physician training and mentoring capacity with global centres of excellence
- Three successful acquisitions to-date delivering **expanded commercial reach**
- **Licensing opportunities** with major Robotics players, with first deal announced with **Intuitive** in May 2022



INTUITIVE



Powered by
**kamaptive
technology**

2016 / 2017

- IPO
- Regulatory clearances and first early clinical use

2018 to 2019

- Start of roll out of clinical use via distributors

2020 to 2021

- Acquisition of Albyn Medical
- Acquisition of Boucart Medical
- Opening of US HQ in Danbury
- Global Pandemic with Covid-19

2022

- Global commercialisation expanding at pace in USA, EMEA and APAC
- Kamaptive Licensing Deal with Intuitive and first revenues

Commercial & Operational Highlights



Growth in revenue driven by Creo's core technology underpinned by stable revenue from consumables business

• Progress in roll-out of Creo's core technology

- Doubling the number of clinicians able to provide training (since Jan22)
- Creo's Pioneer clinician education programme expanded to allow simultaneous multijurisdictional training
- Doubling in the volume of procedures and regular users of Speedboat Inject vs. H221
- New market penetration, as Speedboat Inject used to treat multiple POEM procedures in the US and in EMEA a GIST procedure
- Commercial activity in Asia-Pacific ("APAC") resumed as the region emerges from COVID, with Speedboat Inject training sessions held in multiple locations, most recently in Hong Kong and Bangkok with clinical cases following

• Significant licensing milestones driven by Kamaptive Technology

- Collaboration agreement signed with Intuitive under Creo's Kamaptive licensing programme to optimise certain Creo products for use with Intuitive's robotic technology
- First revenues from Kamaptive licensing programme received
- This validates the strength of our technology and adds credence to our partnering approach.
- Clear demand for Kamaptive driving development towards robotics - huge market underserved by advanced intelligent energy - open opportunity

• Continue to strengthen commercial footprint

- Expanded US sales channel to bundle Creo's core technology with Creo Europe consumable GI products
- Singapore regional hub opened with a direct sales and marketing presence in the APAC region


• Ongoing discussions with third parties on potential licensing opportunities



Speedboat and the entire Creo platform represent one of the most innovative contributions to endoscopic energy delivery in the past several decades...

Dr Blair Jobe

Director of the Esophageal and Lung Institute, Allegheny Health Network, USA



Anything is possible with the right approach

Global Reach, Global Markets

(Oct 2022)



4,800+
Customers

316
People

14

Offices

5m+
Products
shipped

9 Direct Countries

- USA, UK, Belgium, Luxembourg, Germany, France, Spain, Hong Kong

26 Indirect Countries

- 26 Indirect signed
- 10 in negotiation
- EMEA, APAC & LATAM focus

316 People

- 160 R&D/Ops
- 104 S&M
- 52 G&A
- 23 USA
- 287 EMEA
- 6 APAC

5m+ Products shipped

- >7m inbound Supply chain
- £50m p/a manufacturing capacity
- 8 service centres across 7 countries

Sales Pipeline

- >250 Qualified targets growing to 400 in 18 months
- Potential for each customer to be min \$50k per annum

14 Offices

- UK, USA, Belgium, Germany, France, Spain, Singapore

Americas

US HQ with Direct Sales in various locations

EMEA

Direct Sales in UK, Germany, Spain, France, Belgium, Luxembourg. Distribution Partners under direct management including Italy, Holland, Turkey, South Africa, Poland and Israel

APAC

Distribution Partners under direct management including India (North & South), Taiwan, Vietnam, Hong Kong, Thailand, Australia, South Korea, Malaysia, Sri Lanka, UAE



Anything is possible with the right approach

Creo – A Global Company

Around the World in 80 days

Follow us on Twitter & LinkedIn  
@CreoEndoscopy and @CreoMedical



ORSI Academy, Belgium



Baylor Simulation Lab, USA



Endo 2022, Japan



Chulalongkorn Hospital, Thailand



Hospital Universitario, Spain



EMIS Research Facility, France



East Kent Hospital, UK



Shamir Medical Center, Israel

Anything is possible with the right approach

Patients



"They said a few years ago I would have ended up with a colostomy bag for six months to a year.

If that was the option to keep me alive I would have taken it, but now I feel like I've got off virtually scot-free.

One of my closest friends died of bowel cancer and that made me so frightened. I can't thank the team enough for everything they have done. They were brilliant and I owe them my life."

**Retired Maths Teacher, Chris Grayling - 67,
From Hamstreet near Ashford, UK**

Launching our Endotherapy Accessories in the US



Areas to target

- Resection, Dissection, Myotomy

Commercial Impact

- Strong margins
- Excellent link to POEMs case
 - 4 clips to close incision
 - ~\$400 per case
- Global distribution possible following taking manufacturing responsibility
- Plan is to evolve with our partners with customer feedback to deliver increase in range and any specific needs
- Long term partners could be Kamaptive development partners enhancing devices powered by Kamaptive
- Targeting 80% of revenue from Creo Manufactured Products



Advanced Energy

Product Portfolio


CROMA Advanced Energy Platform

CROMA delivers advanced bipolar RF and controlled super high frequency microwave energy through a single accessory port to Speedboat Inject, providing precise resection, dissection and coagulation capabilities



Speedboat Inject

Speedboat Inject is the first Advanced Energy multi-modal instrument designed for flexible endoscopy that can deliver both advanced bipolar RF and microwave energy from a single device



Endotherapy Accessories

Product Portfolio

Hot & Cold Snares

Used for EMR and polypectomy based on lesion size. Cold snares are used for smaller lesions, while hot snares are for larger vascular lesions where bleeding may occur

MicroBlate™ Fine Treats First Pancreatic Tumours



Carlos Robles Medranda - Global KOL and trainer

- Recognised international KOL provide fast validation and product iteration
- 6cm tumour treated in December 2020
- CT scan two months post ablation indicated no tumour
- Creo's technology enabled the patient to have Christmas with their family!
- All patients treated had successful ablations

Cases are now taking place in the EU with all global cases being followed up as part of a multi-site global registry



PANCREATIC CANCER

- 4th largest cancer in the world
- **Highest mortality rate** of all major cancers.
- **74%** of patients die within the first year of diagnosis
- **90%** of pancreatic cancer patients will die within five years of diagnosis
- No current screening – this presents a huge opportunity when screening starts
- **Estimated cost of MicroBlate Fine procedure - c£3-4k**


MicroBlate Fine Microwave Ablation (MWA) of NET Tumour

EUS Guided MWA

CT Scan 2 Months Post Ablation



Anything is possible with the right approach





Microwave energy allows for non-stick coating at distal end to prevent tissue sticking

MicroBlate Fine – Case Report



Dr Sundeep Lakhtakia
AIG Hyderabad, India



Patient History: 64Y / Male patient has a Neuroendocrine Tumour (NET) in the pancreas, measuring 25mm x 15mm size

Ablation Time: 120 s (2 min) applied twice due to irregular shape of the mass

Follow-Up: CT in 1-2 months




Anything is possible with the right approach


Chepstow Site



- Acquired site in H2-21 for £4m, mortgage completed for £2.25 plus grant of £800k from Welsh Government
 - Landlord was selling hence need to acquire and retain production at current site – Risk Mitigation
 - Mortgage cost equal to annual rent
- Have capacity and relevant plan for next 2-3 years
- GBR (CROMA)
 - Last 4 months, production averaged a monthly build rate of over 20 a month
 - Capability to produce 32 per month through headcount increase
 - Expect light touch maintenance for products in the field
- SAAR (Devices)
 - New layout and area plan created to facilitate growth in production demand and allow multi products to be built simultaneously
 - Supporting all new product launches: Speedboat inject; SpydrBlade; Speedboat Flush; Microblate Flex; Microblate Fine
 - Production output has rose month on month in 2022
 - Sharp increase in requirements to support current and 2023 demand
 - Currently producing over £300,000 of product per month
 - Capacity for 100k devices per year with minimal change



- >90m² increase (50% bigger)
- 5 lines, 7 devices
- Installed capacity approx. 200 of each device per week
- Flow processing
- Standardised stations



Anything is possible with the right approach



**What Does it
Mean...**



**CREO
MEDICAL**

Creo Growth – existing products

1. US surgical procedure volumes 2010, Millennium Research, RPUS43SV10, February 2010
2. Gastrointest Endosc 2014; 80:133-43
3. <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence#heading=Zero>
4. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642[Published errata in Gastroenterology 1997;112:1060 and 1998;114: 635]



USA

16m screening colonoscopies are performed per annum in the US¹

1.1m will find a lesion which should be treated²

Approximately **50%** of those lesions are surgically removed¹

550,000 = 0.17% of population



UK

CRC incidence rate in UK is **41,804**³

50%⁴ of **>2 cm** lesions become cancerous

~100,000 lesions found greater than 2 cm

100,000 = 0.16% of population

Basic Business Model - GI Resection

Each device costs ~\$1k and each user performs two procedures per week → Each independent user is a \$100k customer!

- **>100 users** trained creates a >\$10m pa business opportunity
- **500 independent users** creates a \$40-50m business – target within 3-5 years
- **2000 users** creates a \$200m pa business opportunity (within 10 years)

Market Size by Population



EUROPE
~0.7 billion



USA
~0.3 billion




APAC
~1.5 billion



~4m procedures per year (**0.165%** of population)

~25-30k generators required @ 2-4 devices per week



Target over 2000 customers with 500 Independent users within 3-5 years

Anything is possible with the right approach


Sales Funnel




PIONEER
CLINICAL EDUCATION PROGRAMME



Opportunity Funnel – 339 – all qualified –
c100% growth since start of 2022



Device User Forecast



Attendees

Dr Mumtaz Hayat	UK
Dr. Nisha Patel	UK
Mr Joseph Sebastian	UK
Dr Vanja Giljaca	UK
Dr Neo Seabi	South Africa
Gloria Fernández Esparrach	Spain
Álvaro Terán Lantaron	Spain
Dr. Ricardo Mejia	Chile
Dr. Ido Bar Yishai	Israel
Dr. Erez Skapa	Israel
Dr. Gonzalo Ross	Chile
Dr Sergei Vosko	Israel



International Pioneer Event March 2022

- 12 Doctors in attendance
- 2 are now independent users
- 2 are now users in training
- 7 are being mentored
- 1 Strategic KOL, ESGE

Anything is possible with the right approach

Creo Core Technology




CROMA
powered by kamaptive technology



MicroBlate™
Flex

Flexible microwave ablation device
Designed for soft tissue ablation where
flexibility and small diameter is required



MicroBlate™
Fine

Tissue microwave ablation devices for
ablation of tumours in a wide range of
tissue types – and the smallest
microwave ablation device we know of*



SpydrBlade™
Flex

Surgical device combining Speedboat
blade and precise microwave coagulation
in a unique multi-modal jaw design



Speedboat™
Inject

Speedboat is our flagship advanced
energy device product with over 1,000
procedures performed using the device




SlypSeal™
Flex

Haemostasis device leveraging our
unique 'non-stick' technology. The only
'non-stick' electrosurgical haemostasis
device technology in the market*



Anything is possible with the right approach

Treating more patients, driving Growth



Advanced Energy


- Strengthen Portfolio
- Drive Utilization
- Clinical and Economic Data

Complimentary Devices

- Bundle AE devices with additional procedural devices
- Expand access to a larger market with higher volumes

Expanded Advanced Energy Portfolio

- High-volume devices
- New Applications
- Broader Target Customers
- Replace Generators



Utilisation	2022	2023	2024	2025	2026	2027
Devices / mth	0.8	2.3	4.8	7.2	8.0	9.2

Speedboat

Increase Utilization

- Upper GI Clearance: Expands utilization with CE Mark
- Approvals and rollout in more countries in APAC and LATAM
- Smaller Scope compatibility drives EMR and Surgery conversions

SpydrBlade Flex

Target Speedboat Users and trainees for rapid adoption

- New applications will increase utilization LGI-Pedunculated Polyps, ESD UGI-POEM(all), Zenkers etc

MicroBlate Fine

Limited Release in 2023 to Worldwide adoption 2024

- Published Clinical data increases referrals from tumor boards ('23)
- Migration of RFA users to MW with pre-clinical publications ('23/'24)
- Indication Expansion ('24+)

MicroBlate Flex

Initial products to run Clinical Trials

- Current and targeted clinical trials '23
- New indications (varicose veins, kidney)
- Pre-Clinical - Varicose Veins ('23,published),

Anything is possible with the right approach



Training



PIONEER

CLINICAL EDUCATION PROGRAMME

Growth of the Pioneer Programme



PIONEER
CLINICAL EDUCATION PROGRAMME



With a pipeline of experts wanting to be part of the Creo Journey we have significantly increased our training capacity post-pandemic. 2022 has seen:


- **200% increase in trainers vs 2021**

Global experts **providing training all over the world**

- **350% increase in ex-vivo activities vs 2021**

Used to understand the skill, mentality and teamwork abilities of trainees prior to them attending the full Pioneer training journey.

Means **more committed trainees** and **less time and money wasted** on unsuitable trainees either unable or unwilling to progress



Ability to run larger, more cost-effective in-vivo Training Programs


- Increase in trainers and demand allowing training events of 10 or more trainees at a time to become the norm, with **cost efficiencies in the per head cost of training** and time away from clinical practices for staff and trainers.
- Ave cost per training dropped from £8k (2019) to £5k (2022). Total customer acqn cost estimated between £25-40k depending on region. Expect to drop through 2023 and beyond to £15-20k

Increase in Live training events

- Using our expanding group of experienced users we have **increased Live Case training** events across all regions with 12 events in 2022 and 20+ planned for 2023

Launch of the Pioneer Clinical Community

- Sharing learning and experience between clinicians peer to peer is the fastest way to educate and accelerate change of practice within the medical community. The Pioneer Community gives doctors a closed and secure way of **sharing information on all Creo technology**



Continued Growth Plan

- **Creo Clinical Resources Driving Utilization**
2022 was the breakthrough year for establishing our clinical resources. We have added a Clinical Education Specialist in all geographies to be able to train, mentor and accelerate the pathway from trainee to user. This will continue to grow as we enter further new markets.
- Wider suite of devices does not require such an intensive level of training as those to date so it will be **easier, faster and more cost effective to train users** on these devices
- As the **Pioneer Programme is becoming recognised globally as a World-class programme**, we will soon look to charge for the training, starting with a course fee and moving towards trainees covering early costs of training by 2024

Health Care Professionals



KOL View – Dr Blair Jobe



Dr. Blair Jobe, **Director of the Esophageal and Lung Institute** and member of the **American Board of Surgery** and **American Foregut Society**.

Nationally renowned pioneer in the field of minimally invasive surgery and endoscopic therapy for the treatment of esophageal cancer, Barrett's esophagus, esophageal motility disorders and gastroesophageal reflux disease (GERD).


Dr Jobe has been particularly prolific in using Speedboat to perform Peroral Endoscopic Myotomy (POEM) procedures.



"Speedboat and the entire Creo platform represent one of the most innovative endoscopic energy delivery in the past several decades. The operator is now liberated beyond the confines of present techniques and apply surgical oncologic principles (en bloc vs. piece meal resection) to both staging and definitive endoscopic therapies within the GI tract.

It is my hope that scope of this technology will be broadened to include intra-abdominal and thoracic procedures."

New procedures



Validating Clinical and Economic Outcomes



CREO
MEDICAL

Validating Clinical and Economic Outcomes

- **Registries:**

- 2 active registries currently with a focus on SSD (both lower GI and Upper GI) and POEM,
- Yielding valuable data on safety, efficacy, and shortened learning curve.

- **Publications:**

- 2 papers encompassing 300+ procedures from ESD physician, and EMR convert with world renown global KOL co-authors.
- Submissions to high value GI Journals).

- **Podium Presentations:**

- Live endoscopy events and data presented at International GI congresses in US, EU and APAC

- **Case Studies/Patient Testimonials:**

- Continued expansion of clinical library encompassing procedures throughout GI Tract

- **Societies:**

- Registry data will support a shift in training guidelines, due to the validated safety, and shortened learning curves



Anything is possible with the right approach



Clinical Case Studies

Clinical Case Study - India



Speedboat[™]
Inject



Speedboat Submucosal Dissection (SSD) for G-POEM

Dr. Mohan Ramchandani | Director of Interventional Endoscopy, AIG Hospitals, Hyderabad, India



Patient History

A 46 year old female presented with chief complaint of post- prandial vomiting containing food particles , 2-3 hour after meals , for 2 months. She also complained of post prandial fullness for 5 years. She had no history of significant weight loss , abdominal pain or altered bowel habits. She is known case of Type 2 Diabetes (Controlled , HBA1c 6.7 %) and hypertension on regular treatment.




Outcome

- Technical success -The procedure of endoscopic pyloromyotomy was successfully achieved with adequate relaxation of pylorus as assessed by endoscopy.
- Adverse events-There were no intraprocedural complications like bleeding or mucosal perforation. Delayed complication like delayed bleeding or mucosal dehiscence were not noted.
- Post operatively clinical response-There was significant improvement in symptoms with improvement of GCSI score
- Post operative Gastric Emptying showed normalization



The use of this multi-functional device has many advantages including precise delivery of energy minimising collateral injury, and the reduction in the need for instrument exchanges for coagulation, therefore, reducing operative time significantly.



Completely relaxed pylorus after the myotomy

We demonstrated that a case of gastric peroral endoscopic myotomy can be successfully performed using advanced energy and the Speedboat Inject Device.

Clinical Case Study - USA



Speedboat[™]
Inject



Speedboat Submucosal Dissection (SSD) Using Advanced Energy for a LST- mixed lesion in the rectum extending to the dentate line

Dr. Salmaan Jawaid | MD, Therapeutic Endoscopist-Advanced Tissue Resection,
Baylor College of Medicine/St Lukes Medical Center Assistant Professor of Medicine



Patient History

A 54-year-old female presented for her initial screening colonoscopy and was found to have a 35mm LST- mixed lesion in the rectum extending to the dentate line. The lesion demonstrated a central nodule and contained depressed areas within the periphery. Biopsies revealed tubular adenoma with high-grade dysplasia.




Outcome

- The entire procedure was completed in 65 minutes with no immediate complications.
- The patient was discharged home after the procedure as she had no pain around the rectum. Even 24 hours after the procedure, the patient reported no pain.
- Final pathology revealed tubular adenoma with high-grade dysplasia with clear vertical and lateral margins, demonstrating a curative dissection.



Use of the Speedboat Inject devices singlehandedly allowed safe and efficient curative resection of a large rectal lesion that extended to the dentate line. Its successful implementation prevented a major surgery, which carries inherent long-term complications.



Final
resected
specimen

Clinical Case Study - UK



Speedboat[™]
Inject



Speedboat Submucosal Dissection (SSD) Using Advanced Energy on a Mid-Rectal Lateral Spreading Tumour with Focal Depression

Dr Iosif Beintaris, Consultant Gastroenterologist, North Tees and Hartlepool NHS Foundation Trust, UK



SSD is an efficient technique for safe en-bloc resection of advanced polyps of the colorectum. Alternatives for this lesion would be piecemeal EMR that would have led to histopathological confusion with regards to completeness of resection, and TEMS/TAMIS.

Patient History

A 70-year-old man with rectal bleeding and positive FIT was referred for colonoscopy, which picked up a 30 mm mid-rectal lateral spreading tumour with focal depression (LST NG-D) (fig. 1).



Outcome

- En Bloc resection of the lesion was achieved. Histology spoke of a high-grade tubular adenoma
- No intra-procedural/ delayed complications were noted. This was a day-case procedure (same day discharge).




En-bloc resection of the lesion was achieved



Powered by
**kamaptive
technology™**

Kamaptive™ – Creo's Proprietary Intelligent Energy Platform




Intelligent energy with safety at heart.

- Energy with finesse and intelligence
- Heightened controlled accuracy
- Eliminate collateral damage
- Intuitive adaptive interface

What is Kamaptive Technology?


Kamaptive is Creo Medical's proprietary intelligent energy technology, found at the heart of all Kamaptive enabled Advanced Energy platforms and devices.

Kamaptive represents seamless and empowering access to next level, game-changing patient outcomes, through use of full spectrum energy in surgical, medical and therapeutic applications.




CROMA

Kamaptive Technology's architecture allows multiple Creo Development teams to design, test and build innovative devices independently whilst functioning with the CROMA Platform without complex software changes or menu options for users.



Miniaturised


Creo Medical has been working to adapt Kamaptive Technology to miniaturised hand-held devices for heightened accuracy and control. The intuitive intelligence of the interface allows for the platform to be versatile and resilient in scale and function.




New Possibilities

Kamaptive's full spectrum adaptive technology allows for partnership opportunities in new and innovative fields from robotics to laparoscopy. Kamaptive Technology intuitively adapts to the specific tool in use, self provisioning and intelligently enhancing the settings of the CROMA Platform for the purpose of the device being used.

Significant Single Use Market Opportunity



Source: Intuitive Surgical. FactSet consensus estimates



c. **49** million
Open + Lap + Robotic
procedures globally

growing to c. **67** million in 2030

- Currently lack of advanced energy within Robotics
- Harmonics cannot be delivered through robotic infrastructure just like flexible devices

“ Robotic surgery has been growing rapidly over the past fifteen years and has enabled surgeons to do more and more complex surgery to help improve patient outcomes. However, it is a frustration of robotic surgeons that we still have to use a separate laparoscopic Advanced Energy device by hand, through another trocar, because the robotics companies still haven’t developed Advanced Energy devices to match what has been available to us as laparoscopic surgeons for over twenty years.

To continue to push the boundaries of what is possible, the robotic companies need to address this. Only when the robotic systems have their own advanced energy devices to enable a totally robotic procedure , will the robotic approach explode.”

Professor Mohamad Abu Hilal, Chair of the International Minimally Invasive Consortium for Pancreatic Surgery

Source: Intuitive 2021 earnings estimate


Anything is possible with the right approach

Source: CitiBank Report 2018 (various sources). GM Insights

Robotics Partner Opportunity

“Robotics is happening right now. When somebody cracks the advanced energy dilemma that still exists for all systems, then there will be no stopping it's expansion.”

Professor Jared Torkington, Colorectal Surgeon, Professor of Surgical Innovation, Cardiff and Vale Health Board



Over 2m pa Robotic Procedures pa,
growing fast.

Surgical Robotics market growing
at a 14-20%+ CAGR.

Hospitals adopting RAS experienced
general surgery procedure utilisation
increase from <2% RAS to >15% RAS in 6
years

Robotic Surgery currently predominantly limited to:

- Old cold blade cut, sutures and staplers
- Suboptimal and limited functionality for grasping and manipulation
- Narrow energy platforms

Offering little additional capability over existing laparoscopic or open surgery procedures

Currently working with a number of Robotics partners to establish device partnerships

Anything is possible with the right approach

Collaboration Agreement with Intuitive



Creo technology to be adapted for use with robotic-assisted surgical platform

- Multi-year collaboration agreement with Intuitive – a **global technology leader** in minimally invasive care and the pioneer of robotic-assisted surgery.
- Agreement will see optimisation of certain Creo products to be compatible with Intuitive's state of the art robotic technology.
- Agreement also provides a framework to allow joint clinical studies to be undertaken and includes a number of milestone payments to be made to Creo.
- Future royalty structures have been agreed which will apply when products are commercialised.
- First revenues from Kamaptive licensing programme received in H1-21 with follow revenue in H2-22 and 2023

INTUITIVE



Technological advancements are facilitating a paradigm shift in the way many surgical procedures are delivered and we look forward to working together to enable additional options for patients using this combined pioneering technology.

Craig Gulliford



kamaptive[™]
technology

Kamaptive Opportunity



- All Kamaptive opportunities planned to be funded development programme
 - R&D on current devices complete
 - Creo will be paid to develop new ones...or
 - Paid to iterate future devices
 - All aim to be cash positive out of gates – strong margin and/or future royalty streams
- Initial deal with Intuitive
- Many additional robotic companies – all need Advanced Energy
 - The worldwide surgical robotics market created \$4.71 billion in 2018
 - Assessed to reach \$15.43 billion by 2029
 - Huge market opportunity
 - Largest currently USA
 - Fasted growing market – APAC
- Targeting further deals for both exclusive and non-exclusive relationships across multiple markets and products



	Intuitive	Partner 2	Partner 3
Initial Discussions / NDA			
Concept Definition / Compatibility			
Proof of Concept			
MOU			
LOI			
Target Definitive Agreement	INTUITIVE	Q4-22	Q4-22

Anything is possible with the right approach



Summary

Two Specific Areas of Focus




IPO only had Core Creo products, however business has evolved into two Core Markets

1. Core Creo Products and Devices

- Three specific areas
 - USA
 - EMEA
 - APAC
- R&D completed on product range
- Sales and clinical team in place
- Training programme established and delivering

2. Robotic opportunity – Kamaptive

- Initial deals in place with more in discussion
- Each customer has potential for multi device contracts
- Development Roadmap fully funded leveraging Core Creo products
- Less burden of regulatory clearances on Creo
- Significant license upside post product launches
- Continued lower cost research to drive development of licensing programme



Core Creo

Advances in single-port laparoscopy, robotic surgery, natural orifice transluminal endoscopic surgery
& flexible endoluminal endoscopy
herald a new era of healthcare

\$3-4bn GI Endoscopic Instrument Addressable Market
with minimal competition

Robotics

Robotic surgery accounts for circa 5% of all procedures
Over 2m pa Robotic Procedures, **growing fast.**

Surgical Robotics market growing at a 14-20%+ CAGR.

Hospitals adopting RAS experienced general surgery procedure utilisation increase from <2% RAS to >15% RAS in 6 years

Dominant Handheld Technology inappropriate for Robotic Applications



2023 and Beyond – Building on Regular Users and delivering Kamaptive Opportunity

- Operate EMEA, US and APAC core business from **solid foundation** with no increase in the cost base
 - Targeting 80% of revenue from Creo Manufactured Products
 - **EMEA** profitable within 2023 including core product, admin, manufacturing and sustaining engineering costs
 - **USA** will have 15-20 sales staff (blend of independent and direct), with direct investment to achieve **profitability** in short / medium term clear path to break even – c100 users
 - **APAC** – slower out of pandemic, 20+ dealers signed, **clinical education driving revenue**, profitability in reach off low-cost base. Significant long term **revenue potential**. China planned in 2024 – discussing JV potential.
 - Continue to Grow KOL centres of excellence into **regionalised training centres** as part of Pioneer Clinical Education Programme – this is for all regions
 - **Dramatically expand the market** potential by training "routine endoscopist" with the foundations we have built
- Kamaptive licensing business
 - Current signed deal drives team of 10-12 on a **cash positive** basis
 - Significant investment and **increasing demand** for robotic products with a clear revenue pipeline

Break even and Beyond



Speedboat[™]
Inject



Anything is possible with the right approach



CREO
MEDICAL

**Anything is
Possible
with the Right
Approach**



CREO
MEDICAL